A six-chart data feature from Pittsburgh NPR affiliate 90.5 WESA attempts to render the first Trump administration's effect on National Institutes of Health research funding into visual evidence. The headline-level claim: NIH funding has been "reshaped," not merely trimmed or restored, and the piece makes that case graphically.

The visualization approach matters for R&D managers and principal investigators who track federal appropriations. A chart series compresses year-over-year grant counts, indirect-cost rates, and study-section priorities faster than a 3,000-word feature. Six charts is also a deliberate constraint — enough panels to break the data into mechanism categories, few enough that readers retain the shape.

What does the WESA piece likely cover?

The headline invokes "reshape" rather than "cut" or "expand." In NIH budget vocabulary, that word choice usually points to one or more of the following mechanisms:

• Success rates at R01-equivalent paylines
• Allocation across the largest extramural institutes — NCI, NHLBI, NIAID, NIMH
• Specific program lines: Common Fund, HEAL, Cancer Moonshot
• Indirect-cost reimbursement formulas
• F-series fellowship stipend scales

WESA's chart panels will likely map to some subset of these. Without the chart annotations or methodology line, the specific endpoints — base year, comparison year, institute list — are not verifiable from the headline alone. That limitation is typical of visualization journalism aimed at general audiences: the visuals carry the argument, the captions carry the numbers, and the methodology is often a single line.

Why the institutional context matters

90.5 WESA is a public-radio newsroom, not a scientific publisher. The piece likely draws on NIH RePORTER, Office of Budget reports, and possibly FOIA-released materials on study-section composition. None of that infrastructure is visible from the headline link itself.

For research administrators, the test of any such visualization is whether the underlying data tables are linked or downloadable. WESA's previous data features on Pennsylvania NIH flows and regional SBIR/STTR awards have generally linked source spreadsheets. If this piece follows that pattern, R&D offices can pull the raw figures and reconcile them against their own grant-tracking systems.

What six charts cannot show

A six-chart ceiling forces editorial choices. Several variables that R&D managers monitor do not reduce cleanly to bar-or-line form:

• Multi-year commitments obligated before policy shifts took effect
• Supplement mechanisms — administrative, competitive, and pandemic-era — that sit outside base appropriations
• Institute-specific set-asides Congress directs in report language
• The 12- to 18-month lag between an appropriation and a study-section payline response

A chart series can show the appropriation line; it struggles to show the grant-award line that follows it. For anyone building a five-year portfolio forecast, that lag is the operational variable.

How should R&D offices use this kind of feature?

Treat it as a starting prompt for RePORTER queries, not a final accounting. The interesting questions are downstream:

• Which institute's success rate moved most, and is that consistent with WESA's panel?
• Did the chart series account for supplement dollars that propped up apparent totals?
• Does the indirect-cost calculation reflect pre- or post-policy rates?

A visualization from a credible regional outlet signals where to look. The reconciliation work remains in the reader's hands.

The piece arrives as FY2026 congressional appropriations move through committee, with NIH facing a continuing-resolution pattern that obscures the actual allocation trajectory. The next chart worth waiting for will likely compare the second Trump administration's first-year appropriations against the first administration's final-year figures — a benchmark the current WESA series cannot yet supply.